UPDATE: Canaccord Maintains Hold On Biogen, Raises Target To $305 Notes 'There is still a lot of uncertainty and investor skepticism as it is unclear whether the FDA could approve adu based on one successful EMERGE trial supported by ENGAGE that failed'